The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Discovering Anti-Cancer Drugs via Computational Methods
Open accessAbstract
Developing a new drug is a complex, dangerous, expensive and time-consuming venture. The traditional drug development process is estimated to take 12 years on average and more than 2.5 billion USD to complete. Reducing the cost and speeding up the development of new drugs have become a challenging and urgent problem facing the pharmaceutical industry. Computer-aided drug discovery (CADD) combined with new experimental technologies promises to make finding new drugs faster, cheaper and more effective thanks to the reduced cost of computational methods and the increased availability of three-dimensional structural information. The application of computational tools to drug discovery, including anticancer therapies, has grown steadily for the past years, which has had a significant impact on the design of anticancer drugs and drug candidates over the years and has provided fruitful insights into the field of cancer. In this article, our objective is to provide an overview on the different subareas of the drug discovery process with a focus on anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
(2014) · Cited by 33,419
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Cramer, R. D., Patterson, D. E., & Bunce, J. D. (1988) · Journal of the American Chemical Society · doi:10.1021/ja00226a005 · Cited by 3,931
Johnson, C. O., Nguyen, M., Roth, G. A., Nichols, E., Alam, T., Abate, D., Abd-Allah, F., Abdelalim, A., Abraha, H. N., Abu-Rmeileh, N. M., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30034-1 · Cited by 3,264
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Klebe, G., Abraham, U., & Mietzner, T. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00050a010 · Cited by 1,816
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules.
Gómez‐Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera‐Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru‐Guzik, A. (2018) · Cambridge University Engineering Department Publications Database · doi:10.17863/cam.34134 · Cited by 1,703
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Principles of docking: An overview of search algorithms and a guide to scoring functions
Halperin, I., Ma, B., Wolfson, H., & Nussinov, R. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10115 · Cited by 1,294
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Wang, J.-L., Liu, D., Zhang, Z.-J., Shan, S., Han, X., Srinivasula, S. M., Croce, C. M., Alnemri, E. S., & Huang, Z. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7124 · Cited by 1,201
Prediction of drug–target interaction networks from the integration of chemical and genomic spaces
Yamanishi, Y., Araki, M., Gutteridge, A., Honda, W., & Kanehisa, M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn162 · Cited by 1,147
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Staphylococcus aureus Sortase, an Enzyme that Anchors Surface Proteins to the Cell Wall
Mazmanian, S. K., Liu, G., Ton-That, H., & Schneewind, O. (1999) · Science · doi:10.1126/science.285.5428.760 · Cited by 1,053
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Pharmacophore modeling and applications in drug discovery: challenges and recent advances
Yang, S.-Y. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.03.013 · Cited by 901
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
The computer program LUDI: A new method for the de novo design of enzyme inhibitors
B�hm, H.-J. (1992) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124387 · Cited by 835
Virtual and biomolecular screening converge on a selective agonist for GPR30
Bologa, C. G., Revankar, C. M., Young, S. M., Edwards, B. S., Arterburn, J. B., Kiselyov, A. S., Parker, M. A., Tkachenko, S. E., Savchuck, N. P., Sklar, L. A., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio775 · Cited by 818
Ras proteins: different signals from different locations
Hancock, J. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1105 · Cited by 756
Salmaso, V., & Moro, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00923 · Cited by 666
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach
Kapetanovic, I. M. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.006 · Cited by 662
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
Advancing drug discovery via artificial intelligence
Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.004 · Cited by 654
Self-citationSildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629
Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease
Kaldor, S. W., Kalish, V. J., Davies, J. F., Shetty, B. V., Fritz, J. E., Appelt, K., Burgess, J. A., Campanale, K. M., Chirgadze, N. Y., Clawson, D. K., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9704098 · Cited by 618
Rush, T. S., Grant, J. A., Mosyak, L., & Nicholls, A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040163o · Cited by 600
Large-scale comparison of machine learning methods for drug target prediction on ChEMBL
Mayr, A., Klambauer, G., Unterthiner, T., Steijaert, M., Wegner, J. K., Ceulemans, H., Clevert, D.-A., & Hochreiter, S. (2018) · Chemical Science · doi:10.1039/c8sc00148k · Cited by 584
Drug–target interaction prediction by random walk on the heterogeneous network
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb00002d · Cited by 533
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Huang, S.-Y., Grinter, S. Z., & Zou, X. (2010) · Physical Chemistry Chemical Physics · doi:10.1039/c0cp00151a · Cited by 508 · cited 1×
“Finally, these programs evaluate the putative binding-free energy, which associates the scoring function to determine which compounds are more likely to bind to targets during the molecular docking (Huang et al., 2010).”
BackgroundLennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4928 · Cited by 433
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., Vaishampayan, U., George, S., Olencki, T. E., Tarazi, J. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370
Universal allosteric mechanism for Gα activation by GPCRs
Flock, T., Ravarani, C. N. J., Sun, D., Venkatakrishnan, A. J., Kayikci, M., Tate, C. G., Veprintsev, D. B., & Babu, M. M. (2015) · Nature · doi:10.1038/nature14663 · Cited by 365
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Efficient overlay of small organic molecules using 3D pharmacophores
Wolber, G., Dornhofer, A. A., & Langer, T. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9078-7 · Cited by 312
Inhibitors of the HSP90 Molecular Chaperone: Current Status
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95009-x · Cited by 310
Allosteric coupling from G protein to the agonist-binding pocket in GPCRs
DeVree, B. T., Mahoney, J. P., Vélez-Ruiz, G. A., Rasmussen, S. G. F., Kuszak, A. J., Edwald, E., Fung, J.-J., Manglik, A., Masureel, M., Du, Y., et al. (2016) · Nature · doi:10.1038/nature18324 · Cited by 290
Dias, R., & de Azevedo Jr., W. (2008) · Current Drug Targets · doi:10.2174/138945008786949432 · Cited by 278
Alpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 270
Improvements, trends, and new ideas in molecular docking: 2012–2013 in review
Yuriev, E., Holien, J., & Ramsland, P. A. (2015) · Journal of Molecular Recognition · doi:10.1002/jmr.2471 · Cited by 263
Li, X., & Chen, H. (2013) · Decision Support Systems · doi:10.1016/j.dss.2012.09.019 · Cited by 260
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Reker, D., Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320001111 · Cited by 227
Drugging Undruggable Molecular Cancer Targets
Lazo, J. S., & Sharlow, E. R. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 224
Cheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Urwyler, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.109.002501 · Cited by 207
Entrectinib: First Global Approval
Al-Salama, Z. T., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01177-y · Cited by 172
Copanlisib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0838-6 · Cited by 162
Ivosidenib: First Global Approval
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0978-3 · Cited by 162
Erdafitinib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01142-9 · Cited by 159
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
Sabbadin, D., & Moro, S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400766b · Cited by 158
Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013)
Buckle, D. R., Erhardt, P., Ganellin, C. R., Kobayashi, T., Perun, T. J., Proudfoot, J., & Senn‐Bilfinger, J. (2013) · Pure and Applied Chemistry · doi:10.1351/pac-rec-12-11-23 · Cited by 152
Jarman, M., Barrie, S. E., & Llera, J. M. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm981017j · Cited by 151
Structure of the IFNγ receptor complex guides design of biased agonists
Mendoza, J. L., Escalante, N. K., Jude, K. M., Bellón, J. S., Su, L., Horton, T. M., Tsutsumi, N., Berardinelli, S. J., Haltiwanger, R. S., Piehler, J., et al. (2019) · Nature · doi:10.1038/s41586-019-0988-7 · Cited by 150
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-019-01252-4 · Cited by 150
Encorafenib and Binimetinib: First Global Approvals
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0963-x · Cited by 149
Brigatinib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0776-3 · Cited by 143
Targeting the c-MET signaling pathway for cancer therapy
Liu, X., Yao, W., Newton, R. C., & Scherle, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.997 · Cited by 138
Duvelisib: First Global Approval
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-1013-4 · Cited by 133
Drug target prediction using adverse event report systems: a pharmacogenomic approach
Takarabe, M., Kotera, M., Nishimura, Y., Goto, S., & Yamanishi, Y. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts413 · Cited by 132
Selinexor: First Global Approval
Syed, Y. Y. (2019) · Drugs · doi:10.1007/s40265-019-01188-9 · Cited by 131
Pocket v.2: Further Developments on Receptor-Based Pharmacophore Modeling
Chen, J., & Lai, L. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci600246s · Cited by 129
Performance Evaluation of 2D Fingerprint and 3D Shape Similarity Methods in Virtual Screening
Hu, G., Kuang, G., Xiao, W. J., Li, W., Liu, G., & Tang, Y. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300030u · Cited by 124
Abemaciclib: First Global Approval
Kim, E. (2017) · Drugs · doi:10.1007/s40265-017-0840-z · Cited by 124
GPCR structures in drug design, emerging opportunities with new structures
Tautermann, C. S. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.07.009 · Cited by 120
Targeting Conformational Plasticity of Protein Kinases
Tong, M., & Seeliger, M. A. (2014) · ACS Chemical Biology · doi:10.1021/cb500870a · Cited by 120
Zhang, Q., Zhang, Y., Diamond, S., Boer, J., Harris, J. J., Li, Y., Rupar, M. J., Behshad, E., Gardiner, C. M., Collier, P., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058883 · Cited by 119
Self-citationMuhsin, M., Graham, J., & Kirkpatrick, P. N. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1136 · Cited by 115
Sharp, S. Y., Boxall, K. J., Rowlands, M., Prodromou, C., Roe, S. M., Maloney, A., Powers, M. V., Clarke, P. A., Box, G., Sanderson, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3473 · Cited by 112
Application of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.10.006 · Cited by 105
Midostaurin: First Global Approval
Kim, E. (2017) · Drugs · doi:10.1007/s40265-017-0779-0 · Cited by 105
Ribociclib: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0742-0 · Cited by 104
Born, J., Manica, M., Oskooei, A., Cadow, J., Markert, G., & Martínez, M. R. (2021) · iScience · doi:10.1016/j.isci.2021.102269 · Cited by 103
Cuzzolin, A., Sturlese, M., Deganutti, G., Salmaso, V., Sabbadin, D., Ciancetta, A., & Moro, S. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00702 · Cited by 98
Methods and Applications of Structure Based Pharmacophores in Drug Discovery
Pirhadi, S., Shiri, F., & Ghasemi, J. B. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313090006 · Cited by 96
Felip, E., Barlési, F., Besse, B., Chu, Q. S.-C., Gandhi, L., Kim, S., Carcereny, E., Sequist, L. V. D., Brunsvig, P. F., CHOUAID, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.131 · Cited by 95
Piotrowska, Z., Costa, D. B., Oxnard, G. R., Huberman, M., Gainor, J. F., Lennes, I. T., Muzikansky, A., Shaw, A. T., Azzoli, C. G., Heist, R. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy336 · Cited by 79
Acalabrutinib: First Global Approval
Markham, A., & Dhillon, S. (2017) · Drugs · doi:10.1007/s40265-017-0852-8 · Cited by 73
Machine intelligence decrypts β-lapachone as an allosteric 5-lipoxygenase inhibitor
Rodrigues, T., Werner, M., Roth, J., da Cruz, E. H. G., Marques, M. C., Akkapeddi, P., Lobo, S. A. L., Koeberle, A., Corzana, F., Júnior, E. N. D. S., et al. (2018) · Chemical Science · doi:10.1039/c8sc02634c · Cited by 73
Biochemical network-based drug-target prediction
Klipp, E., Wade, R. C., & Kummer, U. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.05.004 · Cited by 68
Biaoxue, R., & Yang, S. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4214 · Cited by 66
Chiang, Y., Kuo, C., Wu, Y., Chen, C.-T., Coumar, M. S., Wu, J., Hsieh, H., Chang, C.-Y., Jseng, H.-Y., Wu, M.-H., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801649y · Cited by 63
Mendenhall, J., & Meiler, J. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9895-2 · Cited by 63
The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery
Lü, X., Yang, H., Chen, Y., Li, Q., He, S.-Y., Jiang, X., Feng, F., Qu, W., & Sun, H. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180810162944 · Cited by 62
Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Anthony, C. S., Masuyer, G., Sturrock, E. D., & Acharya, K. R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799034950 · Cited by 61
Jorge, S. E., Lucena-Araujo, A. R., Yasuda, H., Piotrowska, Z., Oxnard, G. R., Rangachari, D., Huberman, M. S., Sequist, L. V. D., Kobayashi, S. S., & Costa, D. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1541 · Cited by 60
Hanna, K. S. (2019) · Drugs · doi:10.1007/s40265-019-01241-7 · Cited by 59
Troubleshooting computational methods in drug discovery
Kortagere, S., & Ekins, S. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.02.005 · Cited by 54
Development of The Epidermal Growth Factor Receptor Inhibitor Tarcevatm(Osi-774)
Grünwald, V., & Hidalgo, M. M. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_19 · Cited by 53
Reimann, Z., Miller, J., Dahle, K. M., Hooper, A. P., Young, A. M., Goates, M. C., Magnusson, B. M., & Crandall, A. (2018) · Journal of Health Psychology · doi:10.1177/1359105318800829 · Cited by 51
Exploring a new ligand binding site of G protein-coupled receptors
Chan, H. C. S., Wang, J., Palczewski, K., Filipek, S., Vogel, H., Liu, Z., & Yuan, S. (2018) · Chemical Science · doi:10.1039/c8sc01680a · Cited by 43
Self-citationSu, Y., Long, X., Song, Y., Chen, P., Li, S., Yang, H., Wu, P., Wang, Y., Bing, Z., Cao, Z., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00631-x · Cited by 43
Markham, A., & Duggan, S. T. (2019) · Drugs · doi:10.1007/s40265-019-01212-y · Cited by 42
Tondo, A. R., Caputo, L., Mangiatordi, G. F., Monaci, L., Lentini, G., Logrieco, A. F., Montaruli, M., Nicolotti, O., & Quintieri, L. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b06237 · Cited by 40
Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Al-Salama, Z. T. (2019) · Drugs · doi:10.1007/s40265-019-01194-x · Cited by 37
Hong, J. Y., Price, I. R., Bai, J. J., & Lin, H. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00384 · Cited by 36
Hansch, C. H., & Fujita, T. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01078a623 · Cited by 25
Lu, P., Bevan, D. R., Leber, A. J., Hontecillas, R., Tubau‐Juni, N., & Bassaganya-Riera, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73238-1_2 · Cited by 16
Itoh, Y. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00741 · Cited by 15
Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate
Kotecki, N., Gombos, A., & Awada, A. H. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1613892 · Cited by 11
Kranthi Raj, K., Mathi, P., Prasad, M. V. V. V., Botlagunta, M., Ravi, M., & Ramachandran, D. (2018) · Chemical Data Collections · doi:10.1016/j.cdc.2018.04.007 · Cited by 8
Cited by
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
The Potential Applications of Artificial Intelligence in Drug Discovery and Development
Farghali, H., Kutinová Canová, N., & Arora, M. (2021) · Physiological Research · doi:10.33549/physiolres.934765 · Cited by 72
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Metadata
- Authors
- Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-20
- Volume
- 11
- Pages
- 733-733
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3028161460
- Cited by
- 307
- References
- 115
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.